Volitionrx Ltd (VNRX) Stock Price, Quote & News

Company Profile

VolitionRx Limited, a multi-national epigenetics company, engages in the development of blood tests to help diagnose and monitor a range of cancers, and diseases associated with NETosis such as sepsis in the United States and internationally. It offers Nu.Q Vet, a cancer screening test for dogs and other animals; Nu.Q Nets, detects diseases associated with NETosis such as sepsis; Nu.Q Cancer for monitoring disease progression, response to treatment and minimal residual disease; Capture-PCR, an i...

Industry: Medical Devices

Sector: Healthcare

Phone: 646 650 1351

Website: www.volition.com

Address:

1489 West Warm Springs Road, Suite 110, Henderson, United States

2021er Jul. 18 at 6:39 AM

$VNRX 50d MA over 200d MA

0 · Reply

JarvisFlow Jul. 17 at 1:00 PM

D. Boral Capital has updated their rating for VolitionRX ( $VNRX ) to Buy with a price target of 5.

0 · Reply

SkinnyDude911 Jul. 16 at 6:36 PM

$VNRX HENDERSON, Nev., July 16, 2025 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, today provides an update on the significant commercial and scientific progress of its Nu.Q® Discover program This is goong to Explode. It really has game changer potential.. Het it now s this one could have explode pn a major after markwr climb at anytime. I always feel its easily going to Fly past 1 in very short order. The pet business test alone should be hoghly successful as they make in roads. Ot looks more and more like it will be able to cross over for humans as well. That would truly be a game changer. Get it while you can.

0 · Reply

2021er Jul. 16 at 3:36 PM

$VNRX

0 · Reply

2021er Jul. 16 at 3:21 PM

$VNRX

0 · Reply

SkinnyDude911 Jul. 14 at 4:10 PM

$VNRX I love the stock and the story that's going to push it well over a dollar. Solid-based building and the story has gotten better and better and better. This one is ready to bust up on any real significant news. Which I believe will come sooner rather than later. Definitely a major bull here.

0 · Reply

SkinnyDude911 Jul. 10 at 3:41 PM

$VNRX Volition Announces Groundbreaking Lateral Flow Test for Point-of-Care Quantification of Nucleosomes July 08, 2025 8:00am EDT Game changers.

0 · Reply

SkinnyDude911 Jul. 10 at 2:43 PM

$VNRX Only a matter of time. As the wtory hets better i accumulate. Insiders but. The story gets mote and more promising as profitability is close.

0 · Reply

JarvisFlow Jul. 9 at 12:00 PM

D. Boral Capital has adjusted their stance on VolitionRX ( $VNRX ), setting the rating to Buy with a target price of 5.

1 · Reply

2021er Jul. 8 at 7:22 PM

$VNRX

0 · Reply

Nu.Q® Discover Expands Global Adoption and Epigenetic Innovation

Jul 8, 2025, 8:00 AM EDT - 9 days ago

Volition Announces Groundbreaking Lateral Flow Test for Point-of-Care Quantification of Nucleosomes

Jun 12, 2025, 8:30 AM EDT - 5 weeks ago

Volition Announces MARS Consortium Clinical Study Suggests Nu.Q® H3.1. Concentrations are Closely Associated with Sepsis and Organ Failure

Jun 4, 2025, 9:00 PM EDT - 6 weeks ago

Volition Announces Two Oral Presentations at Asian Meeting of Animal Medicine Specialties

May 19, 2025, 8:30 AM EDT - 2 months ago

VolitionRx Limited Announces Successful Detection of Nucleosomes in Cats

May 16, 2025, 7:19 PM EDT - 2 months ago

VolitionRX Limited (VNRX) Q1 2025 Earnings Call Transcript

May 15, 2025, 5:37 PM EDT - 2 months ago

VolitionRx Limited Announces First Quarter 2025 Financial Results and Business Update

May 12, 2025, 8:30 AM EDT - 2 months ago

VolitionRx Limited Schedules First Quarter 2025 Earnings Conference Call and Business Update

May 7, 2025, 8:30 AM EDT - 2 months ago

VolitionRX Limited: Outlines broad strategy to become the 'NETs company' worldwide through licensing and updates progress of Nu.Q® NETs test adoption

Apr 29, 2025, 8:30 AM EDT - 2 months ago

VolitionRX Limited: Revolutionizing the diagnosis and monitoring of life-altering diseases for both humans and animals in multi-billion dollar markets

Apr 1, 2025, 12:31 AM EDT - 3 months ago

VolitionRx Limited (VNRX) Q4 2024 Earnings Call Transcript

Mar 31, 2025, 4:05 PM EDT - 3 months ago

VolitionRx Limited Announces Full Fiscal Year 2024 Financial Results and Business Update

Mar 28, 2025, 8:00 AM EDT - 3 months ago

Volition Announces Two Poster Presentations at ESMO's European Lung Cancer Congress 2025

Mar 27, 2025, 8:30 AM EDT - 4 months ago

Volition to Host Virtual Investor Event on Nu.Q® Cancer, "A Look to the Future of Cancer Diagnostics", on April 9, 2025

Mar 26, 2025, 8:00 AM EDT - 4 months ago

VolitionRx Announces Pricing of up to $2.3 Million Registered Direct Offering

Mar 25, 2025, 9:30 AM EDT - 4 months ago

VolitionRx Limited Schedules Full Fiscal Year 2024 Earnings Conference Call and Business Update

Mar 21, 2025, 8:30 AM EDT - 4 months ago

Volition's Nu.Q® Cancer Diagnostics Test Aims To Disrupt the Multi-Billion Dollar Liquid Biopsy Industry

Mar 20, 2025, 8:30 AM EDT - 4 months ago

Volition Introduces Nu.Q® Cancer Blood Test in New Industry Primer for Lung Cancer

Mar 17, 2025, 8:30 AM EDT - 4 months ago

Volition Proudly Sponsors the 44th ISICEM Congress

Mar 13, 2025, 8:30 AM EDT - 4 months ago

Volition Signs first ever Nu.Q® Vet Cancer Test Automation Agreement with Fujifilm Vet Systems

Mar 11, 2025, 8:30 AM EDT - 4 months ago

Volition Announces First Patient Enrolled in NTU Hospital's Prospective Validation Study of Nu.Q® Lung Cancer Test

Mar 4, 2025, 8:30 AM EST - 4 months ago

Volition's Nu.Q® Discover Biomarkers to be utilized in Human Clinical Study Sponsored by Leading Pharmaceutical Company for the First Time

Feb 28, 2025, 8:30 AM EST - 4 months ago

Volition Showcases Nu.Q® Vet Cancer Test at the 97th WVC Annual Conference

Feb 6, 2025, 8:30 AM EST - 5 months ago

Volition Signs First Commercial Project Utilizing Rapid High-Throughput Model in the Study of NETosis

Feb 5, 2025, 9:15 AM EST - 5 months ago

Volition to Host Virtual Investor Event on Nu.Q® NETs, "Casting a New Light on Sepsis Management", on February 14, 2025

Jan 30, 2025, 8:30 AM EST - 6 months ago

Large clinical study establishes Nu.Q® NETs H3.1 as an independent predictor of 28-day mortality in sepsis

Jan 8, 2025, 8:30 AM EST - 6 months ago

Volition Issues Business Review 2024

Dec 12, 2024, 8:00 AM EST - 7 months ago

VolitionRx Appoints LifeSci Advisors as Investor Relations Consultants

Dec 10, 2024, 8:00 AM EST - 7 months ago

Study shows Nu.Q® Lung Cancer Test differentiated malignant and benign nodules found by Low Dose CT screening

Dec 6, 2024, 9:00 AM EST - 7 months ago

VolitionRx Announces Pricing of up to $1.9 Million Registered Direct Offering

Nov 15, 2024, 11:47 AM EST - 8 months ago

VolitionRx Limited (VNRX) Q3 2024 Earnings Call Transcript

Nov 14, 2024, 4:10 PM EST - 8 months ago

VolitionRx Limited Announces Third Quarter 2024 Financial Results and Business Update

Nov 8, 2024, 8:00 AM EST - 8 months ago

VolitionRx Limited Schedules Third Quarter 2024 Earnings Conference Call and Business Update

Nov 6, 2024, 4:10 PM EST - 9 months ago

Volition Appoints Timothy I. Still as Chairman

Oct 31, 2024, 8:00 AM EDT - 9 months ago

Multiple studies show Nu.Q® NETs test could predict sepsis patients at risk of deteriorating

Oct 9, 2024, 8:00 AM EDT - 10 months ago

Volition to share new 'NETs in sepsis management' data insights at upcoming webinar

Oct 3, 2024, 8:00 AM EDT - 10 months ago

Volition hosts NETs in sepsis management symposium at ESICM Lives 2024

Sep 30, 2024, 4:10 PM EDT - 10 months ago

Volition Appoints Dr. Ethel Rubin as an Independent Director

Sep 11, 2024, 8:00 AM EDT - 11 months ago

Volition Hosts KOL Roundtable on Sepsis

Aug 15, 2024, 12:11 PM EDT - 1 year ago

VolitionRx Limited (VNRX) Q2 2024 Earnings Call Transcript

Aug 14, 2024, 4:10 PM EDT - 1 year ago

VolitionRx Limited Announces Second Quarter 2024 Financial Results and Business Update

Aug 9, 2024, 8:00 AM EDT - 1 year ago

VolitionRx Announces Pricing of up to $21.5 Million Registered Direct Offering

Aug 6, 2024, 8:00 AM EDT - 1 year ago

VolitionRx Limited Schedules Second Quarter 2024 Earnings Conference Call and Business Update

Jul 9, 2024, 8:30 AM EDT - 1 year ago

Volition appoints PharmaVentures for Capture PCR™ and oncology portfolio licensing

Jun 27, 2024, 8:00 AM EDT - 1 year ago

VolitionRx Limited Issues Mid-Year Review Ahead of 2024 Annual Meeting

Jun 14, 2024, 9:00 AM EDT - 1 year ago

Nexalin Technology and VolitionRX Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV

NXL

May 29, 2024, 8:00 AM EDT - 1 year ago

VolitionRx Limited to Present at Jefferies Global Healthcare Conference

May 14, 2024, 8:24 PM EDT - 1 year ago

VolitionRx Limited (VNRX) Q1 2024 Earnings Call Transcript

May 13, 2024, 4:10 PM EDT - 1 year ago

VolitionRx Limited Announces First Quarter 2024 Financial Results and Business Update

May 8, 2024, 8:00 AM EDT - 1 year ago

VolitionRx Limited Schedules First Quarter 2024 Earnings Conference Call and Business Update

2021er Jul. 18 at 6:39 AM

$VNRX 50d MA over 200d MA

0 · Reply

JarvisFlow Jul. 17 at 1:00 PM

D. Boral Capital has updated their rating for VolitionRX ( $VNRX ) to Buy with a price target of 5.

0 · Reply

SkinnyDude911 Jul. 16 at 6:36 PM

0 · Reply

2021er Jul. 16 at 3:36 PM

$VNRX

0 · Reply

2021er Jul. 16 at 3:21 PM

$VNRX

0 · Reply

SkinnyDude911 Jul. 14 at 4:10 PM

0 · Reply

SkinnyDude911 Jul. 10 at 3:41 PM

$VNRX Volition Announces Groundbreaking Lateral Flow Test for Point-of-Care Quantification of Nucleosomes July 08, 2025 8:00am EDT Game changers.

0 · Reply

SkinnyDude911 Jul. 10 at 2:43 PM

$VNRX Only a matter of time. As the wtory hets better i accumulate. Insiders but. The story gets mote and more promising as profitability is close.

0 · Reply

JarvisFlow Jul. 9 at 12:00 PM

D. Boral Capital has adjusted their stance on VolitionRX ( $VNRX ), setting the rating to Buy with a target price of 5.

1 · Reply

2021er Jul. 8 at 7:22 PM

$VNRX

0 · Reply

SkinnyDude911 Jul. 8 at 12:38 PM

$VNRX Volition Announces Groundbreaking Lateral Flow Test for Point-of-Care Quantification of Nucleosomes Lets Go. The wtory looks better and better. PR Newswire07/08/2025 07:00

0 · Reply

SkinnyDude911 Jul. 8 at 12:34 PM

$VNRX Peess release today.

0 · Reply

2021er Jul. 7 at 2:12 PM

$VNRX golden cross soon

0 · Reply

Bigspydee040 Jul. 3 at 7:12 PM

$VNRX - Yikes !! The expected good news looks like another share dilution. https://ir.stockpr.com/volition/sec-filings-email/content/0001477932-25-004921/vnrx_s3.htm

0 · Reply

Bigspydee040 Jul. 3 at 5:13 PM

$VNRX - looks like more insider buying going on. https://ir.stockpr.com/volition/sec-filings-email/content/0001477932-25-004912/form4.html

0 · Reply

SkinnyDude911 Jul. 3 at 9:14 AM

$VNRX only a matter a time as we climb to 1.00.

0 · Reply

Bigspydee040 Jul. 2 at 8:14 PM

$VNRX - https://www.edisongroup.com/research/nu-q-advances-in-lung-cancer-management/BM-1838/

0 · Reply

2021er Jun. 26 at 4:00 PM

$VNRX

1 · Reply

2021er Jun. 26 at 3:49 PM

$VNRX

0 · Reply

shapenkaas Jun. 25 at 9:43 PM

$VNRX well, that is the first significant up move since years 😄

0 · Reply

SkinnyDude911 Jun. 25 at 3:46 PM

$VNRX look sike a reset as people got bored fast. Its still going to 1.00 but obviously base building and some good news which will come now seem to be the current reality. Anything vlose to .70 would be an add.

0 · Reply

SkinnyDude911 Jun. 24 at 1:49 PM

$VNRX i expected some consolidatiin in the .80s as yhe stock burned thru the .70s quickly. Still heading to over $1.00 but there will be consolation periods due to the telatively fast pace run up.

0 · Reply

Market Cap	72.79M
Revenue (ttm)	1.23M
Net Income (ttm)	-26.97M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-2,192.68%
Debt to Equity Ratio	-0.22

Volume	139,500
Avg Vol	271,876
Day's Range	N/A - N/A
Shares Out	103.98M
Stochastic %K	40%
Beta	1.20
Analysts	Strong Sell
Price Target	$3.12